JP2023096009A5 - - Google Patents

Download PDF

Info

Publication number
JP2023096009A5
JP2023096009A5 JP2023080165A JP2023080165A JP2023096009A5 JP 2023096009 A5 JP2023096009 A5 JP 2023096009A5 JP 2023080165 A JP2023080165 A JP 2023080165A JP 2023080165 A JP2023080165 A JP 2023080165A JP 2023096009 A5 JP2023096009 A5 JP 2023096009A5
Authority
JP
Japan
Prior art keywords
double
stranded
pharmaceutical composition
sequence
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023080165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023096009A (ja
JP7648675B2 (ja
Filing date
Publication date
Priority claimed from JP2020544431A external-priority patent/JP2021514195A/ja
Application filed filed Critical
Publication of JP2023096009A publication Critical patent/JP2023096009A/ja
Publication of JP2023096009A5 publication Critical patent/JP2023096009A5/ja
Priority to JP2025034711A priority Critical patent/JP2025093992A/ja
Application granted granted Critical
Publication of JP7648675B2 publication Critical patent/JP7648675B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023080165A 2018-02-21 2023-05-15 変異P53特異的siRNAを使用した標的癌治療 Active JP7648675B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025034711A JP2025093992A (ja) 2018-02-21 2025-03-05 変異P53特異的siRNAを使用した標的癌治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201801432S 2018-02-21
SG10201801432S 2018-02-21
JP2020544431A JP2021514195A (ja) 2018-02-21 2019-02-21 変異P53特異的siRNAを使用した標的癌治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020544431A Division JP2021514195A (ja) 2018-02-21 2019-02-21 変異P53特異的siRNAを使用した標的癌治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025034711A Division JP2025093992A (ja) 2018-02-21 2025-03-05 変異P53特異的siRNAを使用した標的癌治療

Publications (3)

Publication Number Publication Date
JP2023096009A JP2023096009A (ja) 2023-07-06
JP2023096009A5 true JP2023096009A5 (cg-RX-API-DMAC7.html) 2024-03-22
JP7648675B2 JP7648675B2 (ja) 2025-03-18

Family

ID=67687981

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544431A Pending JP2021514195A (ja) 2018-02-21 2019-02-21 変異P53特異的siRNAを使用した標的癌治療
JP2023080165A Active JP7648675B2 (ja) 2018-02-21 2023-05-15 変異P53特異的siRNAを使用した標的癌治療
JP2025034711A Pending JP2025093992A (ja) 2018-02-21 2025-03-05 変異P53特異的siRNAを使用した標的癌治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020544431A Pending JP2021514195A (ja) 2018-02-21 2019-02-21 変異P53特異的siRNAを使用した標的癌治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025034711A Pending JP2025093992A (ja) 2018-02-21 2025-03-05 変異P53特異的siRNAを使用した標的癌治療

Country Status (8)

Country Link
US (1) US12508277B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755802A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021514195A (cg-RX-API-DMAC7.html)
KR (1) KR102741498B1 (cg-RX-API-DMAC7.html)
CN (1) CN111727254B (cg-RX-API-DMAC7.html)
CA (1) CA3090220A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007450XA (cg-RX-API-DMAC7.html)
WO (1) WO2019164451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3755802A4 (en) 2018-02-21 2021-11-17 Singapore Health Services Pte Ltd THERAPEUTIC TARGETING OF CANCER USING SPECIFIC RNASI FOR P53 MUTANTS
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
CN115820636B (zh) * 2022-09-02 2024-06-11 华南农业大学 靶向TP53基因的sgRNA及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
EP3755802A4 (en) 2018-02-21 2021-11-17 Singapore Health Services Pte Ltd THERAPEUTIC TARGETING OF CANCER USING SPECIFIC RNASI FOR P53 MUTANTS

Similar Documents

Publication Publication Date Title
Zhang et al. The roles of ZEB1 in tumorigenic progression and epigenetic modifications
Moradi‐Marjaneh et al. Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer
Deng et al. Molecular mechanisms of anti-metastatic activity of curcumin
Shi et al. Application potential of toll-like receptors in cancer immunotherapy: Systematic review
Jeon et al. Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer
Potenza et al. MicroRNA‐125a‐5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells
WO2025054270A1 (en) Compositions and methods for treating cancer
RU2017126601A (ru) Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras
Zhang et al. Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp
Ramezankhani et al. Novel molecular targets in gastric adenocarcinoma
TWI855246B (zh) 使用腫瘤治療電場(tt電場)之組合治療
Katsushima et al. Long non-coding RNAs in brain tumors
Boulware et al. Triplex‐forming oligonucleotides targeting c‐Myc potentiate the anti‐tumor activity of gemcitabine in a mouse model of human cancer
JP2018515130A5 (cg-RX-API-DMAC7.html)
Xiao et al. Dig the root of cancer: targeting cancer stem cells therapy
Saad et al. Exosome-mediated crosstalk between cancer cells and tumor microenvironment
JP2018512858A (ja) 癌治療のためのヒト抗原R発現のsiRNA阻害
Krantz et al. Pancreas adenocarcinoma: novel therapeutics
Saatloo et al. Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma
Liu et al. Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2‐dependent pathway
Zhou et al. Circular RNA-regulated autophagy is involved in cancer progression
Peng et al. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line
Nie et al. The role of notch signaling pathway and non-coding RNAs in cancer and inflammation: Progress, therapeutic insights, and future directions
Hou et al. Research on curcumin mediating immunotherapy of colorectal cancer by regulating cancer associated fibroblasts
JP2023126901A (ja) 膵癌細胞の浸潤転移抑制剤